Scarica l'app Stockscreener
27.52
2.93%
-0.83
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Precedente Chiudi:
$28.35
Aprire:
$28.68
Volume 24 ore:
1.12M
Relative Volume:
0.48
Capitalizzazione di mercato:
$3.42B
Reddito:
$715.22M
Utile/perdita netta:
$-250.10M
Rapporto P/E:
-13.56
EPS:
-2.03
Flusso di cassa netto:
$-205.58M
1 W Prestazione:
+0.44%
1M Prestazione:
-8.66%
6M Prestazione:
-30.95%
1 anno Prestazione:
-58.86%
Intervallo 1D:
$27.46
$28.98
Intervallo di 1 settimana:
$27.45
$28.98
Portata 52W:
$24.34
$71.90
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Nome
Apellis Pharmaceuticals Inc
Settore
Industria
Telefono
617-977-5700
Indirizzo
100 FIFTH AVENUE, WALTHAM, KY
Confronta APLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
27.52 | 3.42B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-17 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-21 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-16 | Iniziato | William Blair | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Neutral |
| 2024-02-05 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-02 | Iniziato | Mizuho | Neutral |
| 2023-10-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Reiterato | Citigroup | Buy |
| 2023-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-17 | Ripresa | Stifel | Buy |
| 2022-04-14 | Downgrade | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Reiterato | BMO Capital Markets | Outperform |
| 2021-09-10 | Reiterato | Credit Suisse | Neutral |
| 2021-09-10 | Reiterato | Needham | Buy |
| 2021-09-10 | Reiterato | Oppenheimer | Outperform |
| 2021-09-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-08-19 | Iniziato | Jefferies | Buy |
| 2021-08-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2020-11-19 | Iniziato | Needham | Buy |
| 2020-09-01 | Iniziato | Stifel | Buy |
| 2020-07-20 | Iniziato | ROTH Capital | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-04-01 | Iniziato | Raymond James | Strong Buy |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-11 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2020-01-07 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-12-19 | Iniziato | BofA/Merrill | Buy |
| 2019-11-22 | Iniziato | Wedbush | Underperform |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-08-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
High Growth Tech Stocks In The United States To Watch - Yahoo Finance
Layoff Tracker: Spotlight Goes Dark After Disappointing Preclinical Data for CRISPR Platform - BioSpace
Is Apellis Pharmaceuticals (APLS) One of the Most Oversold Healthcare Stocks to Buy Now? - Yahoo Finance
Sobi, Apellis Seek EMA Nod for Expanded Use of Aspaveli in Rare Kidney Diseases - Marketscreener.com
Apellis Pharmaceuticals, Sobi Say EMA Validated Indication Extension Application for Potential Kidney Disease Treatment - Marketscreener.com
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN - The Manila Times
APLS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
Apellis Pharmaceuticals chief people officer sells shares worth $37,178 - MSN
10 Top Insider Stock Buys And Sells In January - Insider Monkey
Apellis Pharmaceuticals (APLS): Among Top Insider Stock Buys And Sells In January - Insider Monkey
Apellis stock jumps as rare kidney disease therapy succeeds in trial - MSN
Apellis Pharmaceuticals' chief people officer sells $53,275 in stock - MSN
Apellis Pharmaceuticals (APLS) to Release Earnings on Tuesday - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest Update - MarketBeat
HC Wainwright Reaffirms Buy Rating for Apellis Pharmaceuticals (NASDAQ:APLS) - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Mark Jeffrey Delong Sells 363 Shares - MarketBeat
Savant Capital LLC Purchases 9,407 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Entropy Technologies LP Makes New Investment in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Bought by Banque Pictet & Cie SA - MarketBeat
Raymond James maintains Strong Buy on Apellis shares, target at $78 - MSN
Apellis Pharmaceuticals (NASDAQ:APLS investor one-year losses grow to 60% as the stock sheds US$248m this past week - Simply Wall St
(APLS) Investment Analysis and Advice - Stock Traders Daily
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Apellis Pharmaceuticals to Hold Conference Call on Q4 and Full Year 2024 Financial Results - Nasdaq
Apellis Pharmaceuticals' chief business officer sells $10,359 in stock - MSN
Fierce Biotech Layoff Tracker 2025: Encoded trims 29% of team; Inventiva halves staff - Fierce Biotech
Raymond James maintains Strong Buy on Apellis shares, target at $78 By Investing.com - Investing.com South Africa
What 6 Analyst Ratings Have To Say About Apellis Pharmaceuticals - Benzinga
Apellis Pharmaceuticals (NASDAQ:APLS investor one-year losses grow to 58% as the stock sheds US$231m this past week - Yahoo Finance
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Apellis Pharmaceuticals' chief business officer sells $10,359 in stock By Investing.com - Investing.com UK
Apellis Pharmaceuticals Officer Sells Shares to Cover Taxes - TradingView
Piper Sandler maintains neutral on Apellis stock, $32 target - MSN
APLSApellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes - br.ADVFN.com
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Addition... - br.ADVFN.com
Apellis Pharmaceuticals Reports Third Quarter 2019 Business Update and Financial Results - br.ADVFN.com
Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in ... - br.ADVFN.com
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN - br.ADVFN.com
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - br.ADVFN.com
Apellis Pharmaceuticals Inc Azioni (APLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):